Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.60 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 6/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049467 | 0.90 | CTSB (0.62) | CTSBCTSSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3049462 | 0.90 | CTSB (0.62) | CTSBCTSSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8286271 | 0.90 | CTSB (0.62) | CTSBCTSSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3039922 | 0.88 | CTSB (0.77) | CTSBCTSSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8286783 | 0.88 | CTSB (0.77) | CTSBCTSSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3039916 | 0.88 | CTSB (0.77) | CTSBCTSSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8248465 | 0.87 | CTSB (0.67) | CTSBCTSSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3050935 | 0.83 | CTSB (0.63) | CTSBCTSSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3050936 | 0.83 | CTSB (0.63) | CTSBCTSSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8285112 | 0.82 | CTSB (0.66) | CTSBCTSSKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220520-A1 | BIOAVAILABLE COMBINATIONS FOR HCV TREATMENT | JANSSEN SCIENCES IRELAND UC (IE) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220520-A1 | BIOAVAILABLE COMBINATIONS FOR HCV TREATMENT | HAVCR2, CYP7A1, CYP3A4 | CTSB 111/4885CTSS 206/4885KDM4E 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.